PTO/SB/08B (08-03) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
t of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Application Number 09/465,133 INFORMATION DISCLOSURE **Filing Date** 12/15/99 STATEMENT BY APPLICANT First Named Inventor Vegeto, et al. Art Unit 1636 (Use as many sheets as necessary) **Examiner Name** Celine X. Qian **Attorney Docket Number** 213-0041US

Sheet

		NON PATENT LITERATURE DOCUMENTS	
Examiner Cite Inclinitials* No.1 the		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
ca		BAIM, et al., A chimeric mammalian transactivator based on the lac repressor that is regulated by temperature,Proc. Natl. Acad. Sci. USA, 5072-5076, (June 1991).	
ŀ		CLOUSTON, et al., Tissue-specific and hormonal regulation of angiotensinogen minigenes in transgenic mice, EMBO Journal, (1989), 3337-3343, Vol. 8 No. 11.	
		GOSSEN, et al., Tight control of gene expression in mammalian cells by tetracycline-responsive promoters, Proc. Natl. Acad. Sci. USA, (June 1992), 5547-5551, Vol. 89.	
		MCDONNELL, et al., In situ distinction between Steriod Receptor Binding and Transactivation at a Target Gene, Molecular and Cellular Biology, (Sept. 1991), 4350-4355, Vol. 11.	
		POWER, et al., New insights into activation of the steroid hormone receptor superfamily, TiPS, (August 1992), 318-323, Vol. 13.	
		SCHENA, et al., A steroid-inducible gene expression system for plant cells, Proc. Natl. Acad. Sci. USA, (December 1991), 10421-10425, Vol. 88.	
		THEISEN, et al., Inducible tissue specific gene expression in transgenic systems, 1991 Keystone Symposia, J. Cellular Biochemistry, Supp. 15A, B418 Jan. 12-18, 1991.	
V ₂		R.J. WALL, Transgenic Livestock: Progress and prospects for the future, Theriogenology, (1996), 57-68, Vol. 45.	

		
Examiner	Date	2/11/1
Signature	Considered	3 //4/03

EXAMINER: Initial If reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.